Hester Biosciences has informed that the meeting of the Board of Directors of the Company is scheduled on 17/05/2023 to consider and approve the standalone and consolidated audited financial results of the Company for the quarter and year ended 31 March 2023, and to consider the declaration of dividend, if any, on the equity shares of the Company for the financial year 2022-23.
The above information is a part of company’s filings submitted to BSE.